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Abstract
Previous studies have provided strong evidence that the bed nucleus of the stria
terminalis (BNST) is involved in anxiety behavior expression following chronic exposure to
stressful stimuli. Pituitary adenylate cyclase-activating polypeptide (PACAP) mediated signaling
has been linked to the regulation of anxiety related behavior within this region. PACAP
functioning appears to be linked to sex, with PACAP blood levels being strongly correlated with
post-traumatic stress disorder (PTSD) diagnosis and symptoms in female humans (Ressler et al.,
2011). The goal of this study was to further explore this sex specific association by examining
anxiety behaviors across the estrous cycle in relation to the presence or absence of PACAP in the
BNST. This line of inquiry was examined using free cycling non-ovariectomized female rats at
various stages of the estrous cycle that were intracranially injected with either PACAP or a
vehicle. Anxiety behaviors were operationalized by categorizing responses in an elevated plus
maze. Significantly higher instances of anxiety-like behaviors were observed in female rats
injected with PCAP during proestrus and estrus, phases in which ovarian hormones are
fluctuating. Thus, the findings of this experiment lend credence to the idea that sex hormones
interact with the BNST in a manner that can lead to amplified anxiety-like behaviors. Further
investigation of this relationship is warranted in order to further understand apparent sexual
dimorphism in the display of anxiety-related disorders, such as PTSD.
Introduction
Post-traumatic stress disorder (PTSD) is a psychological disorder in which patients suffer
from marked changes in behavior and mental/emotional wellness following the experience of a
traumatic event as defined by the Diagnostic and Statistical Manual of Mental Disorders (5th ed.)
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to include instance in which an individual is exposed to threatened death, serious injury, or
sexual violence. This exposure can occur via direct experience, witnessing a traumatic event,
learning of close friend or family member’s traumatic experience, or undergoing repeated
exposure to traumatic events. Exposure to traumatic events is not unusual—around 60% of men
and 50% of women will experience some form of trauma within their lifetime (Veteran’s Affairs,
2017). While most of these individuals will not go on to develop PTSD, a significant number of
people do. The lifetime prevalence of PTSD within the United States is estimated to be around 7
– 8% (VA, 2017). It is notable that upon examination of PTSD diagnoses in relation to biological
sex, lifetime prevalence of PTSD in men is estimated to be around 5%, whereas prevalence in
women is around 10.4% (VA, 2017). Therefore, even though men are experiencing traumatic
events at a higher rate than women, women are actually more than two times as likely to develop
PTSD at some point in their lives.
To place some of these demographic incidence rates within the context of current world
events, around 30.2% of individuals who have experienced severe COVID-19 infection have
gone on to develop PTSD (Janiri et al., 2021). 55.7% of these PTSD patients were women, and
biological sex was identified as an important risk factor for development of PTSD following
acute critical infection (Janiri et al., 2021).
It is hard to fully estimate the economic burden of PTSD—as to our knowledge, studies
examining health care costs due to PTSD are rather limited. However, it is known that within the
United States the annual cost of anxiety disorders (including PTSD) is estimated to be between
$56.97 billion and $62.76 billion (adjusted for inflation as of 2021) including both direct
(medical) and indirect (productivity/mortality) costs (DeVane et al., 2005). In 2012, the
Department of Defense spent around $294.1 million (around $336.91 million when adjusted for
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inflation) on PTSD-related care for service members (National Academies of Sciences, 2014).
Importantly, this number only includes direct medical costs for service members alone, and thus
does not fully demonstrate the total economic impact of the disorder. One study examining direct
medical costs places the economic burden of PTSD at around $12,815-21,927 (adjusted for
inflation) per patient per year (Ivanova et al., 2011).
PTSD is marked by distinctive “intrusion symptoms”, including recurrent memories and
dreams of the traumatic event(s) (American Psychiatric Association, 2013). Additionally, PTSD
patients often experience dissociation (i.e. flashbacks), in which patients feel as if the event is reoccurring (APA, 2013). Patients will also display psychological distress and physiological
stimulation when exposed to cues that remind them of the traumatic event(s) in some way (APA,
2013). In addition to these intrusion symptoms, patients with PTSD will also display systematic
avoidance of stimuli associated with the traumatic event(s), as well as a pattern of negative
cognitions and mood (APA, 2013). Importantly, individuals with PTSD will also often display
alterations in arousal and reactivity (APA, 2013). This includes, but is not limited to, display of
hypervigilant behaviors and exaggerated startle response, both of which are reflective of a state
of heightened anxiety.
The disruptive nature of the disorder presents a strong incentive and motivation to better
understand the underlying biological mechanisms behind PTSD. By doing so, treatment
solutions can be better optimized to help patients with PTSD.
The Genetics of PTSD.
Previous studies have investigated genetic links with PTSD, in part to identify risk factors
for development of the disorder. It has previously been demonstrated that adult children of
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Holocaust survivors with PTSD are more likely to also develop the disorder compared to adult
children of survivors without PTSD (Yehuda et al., 2001). This observation is consistent with the
idea of a genetic basis for PTSD. Twin studies have also demonstrated that genetic influences are
able to explain a large proportion of PTSD vulnerability, with most variance being accounted for
by non-shared environmental factors (True et al., 1993; Stein et al., 2002).
Although these studies do suggest genetic influences in the development of PTSD, they
do not demonstrate exactly which genes play a role in the etiology of the disorder. More recent
research has focused on identifying genetic targets through genome wide association studies.
Stein et al., 2021 found that several genes are implicated within the expression of the PTSD
phenotype (Table 1). Most notably, MAD1L1, a gene thought to play a role in cell cycle control,
was repeatedly shown to be associated with PTSD across racial and ethnic groups (Stein et al.,
2021). Mutations in this gene have also been shown to be associated with both schizophrenia
(Ripke et al., 2014) and bipolar disorder (Stahl et al. 2019), suggesting that the gene might
represent a general risk factor for the development of psychological disorders.
CRHR1, a gene encoding a receptor for corticotropin releasing hormone (a hormone
highly implicated in stress responding), has been found to be associated specifically with
intrusive symptoms related to PTSD (Gelernter et al., 2019). In individuals diagnosed with
PTSD, the gene has been found to be highly expressed within the amygdala, hippocampus,
frontal cortex, and anterior cingulate – all brain structures thought to be involved in PTSD
circuitry (Stein et al., 2021). Despite this, trials using a CRHR1 antagonist in women were not
found to significantly reduce PTSD symptoms (Dunlop et al., 2017).
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TSNARE1 (involved in intracellular protein transport) and EXD3 (involved in nucleic
acid binding) were also associated with PTSD (Stein et al., 2021). Importantly, TSNARE1 has
been shown to be associated with increased risk-taking behaviors, which might increase the
likelihood that one will experience a traumatic event (Linner et al., 2019). Conversely, EXD3
was actually negatively correlated with PTSD diagnosis, although this relationship was found to
be mediated by socioeconomic status (Polimanti et al., 2019).
Additionally, PARK2 and PACRG were both found to be positively associated with
PTSD diagnosis (Stein et al. 2021). Both of these genes have previously been connected with
susceptibility to leprosy and Parkinson’s Disease, but it is currently unclear what role they may
play within PTSD etiology (Meschede et al., 2020).
Compelling results have also been reported in the case of mutations within ADCYAP1R1,
the gene encoding PAC1, a receptor for pituitary adenylate cyclase activating polypeptide
(PACAP) (Ressler et al., 2011). The association between ADCYAP1R1 and PTSD has been
found in women alone. Because of this sex difference, it is possible that PACAP dysregulation
could play a role in the unequal prevalence between men and women. PACAP is a polypeptide
that has wide ranging effects throughout the body and brain (Shioda, 2000). PACAP has been
referred to as a “master regulator” of stress systems, with its functioning being a point of focus
for the Hammack Laboratory. Accordingly, it is reasonable to examine PACAPergic systems in
relation to stress and anxiety-related disorders such as PTSD.
PACAP.
PACAP exists in two isoforms—PACAP38 and PACAP27 (named for the number of
amino acids assembling the peptide), with the PACAP38 form being predominant within the
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nervous system. It binds to multiple receptor subtypes, including the PAC 1, VPAC1, and VPAC2
receptors. The most common of these is the PAC₁ receptor. This receptor is a G-protein coupled
receptor that is a member of the vasoactive intestinal peptide family. Although different subtypes
are coupled with different signaling pathways, they all ultimately converge on the MEK/ERK
pathway (May et al., 2014). PACAP-mediated ERK phosphorylation then functions to stimulate
cAMP. In this manner, PACAP functions as a neurotransmitter, neuromodulator, and
neurotrophic factor within the central nervous system (Arimura and Shioda, 1995).
PACAP has previously been implicated in the stress response and the display of anxietylike behavior (Hammack et al., 2009; Hashimoto et al., 2011; Roman et al., 2014; KochoSchellenberg et al., 2014; Hammack and May, 2015). PACAP receptors are densely expressed in
anxiety-related regions, and their expression can be upregulated in some of these regions
following exposure to chronic stress. Because of this, PACAP is thought to be involved in stressrelated neurocircuitry within these brain regions, and is implicated in control of physiological
and psychological responding to stress (Ressler et al., 2011; Lehmann et al., 2013).
In this case, variations within ADCYAP1R1 are especially interesting, as the association
with PTSD was located within a single nucleotide polymorphism (SNP) “risk allele” that is
found in conjunction with an estrogen response element (ERE) involved in PAC 1 gene
regulation. Additionally, this SNP was associated with PTSD diagnosis in women, but not men.
Social and cultural factors likely play a role in PTSD development and may contribute to
differences in PTSD prevalence among demographic groups. However, there may also be
differences in underlying biological mechanisms. Note that none of the previously mentioned
genes seem to address a potential biological basis for sex differences observed in PTSD
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diagnosis rates. Thus, ADCYAP1R1 presents itself as a potential candidate for further
illumination of sex-related differences in demographic incidence of PTSD.
In support, in humans that have been diagnosed with PTSD, there is an association
between PACAP and PAC₁ blood levels and sex, with higher levels and expression in females
(Ressler et al., 2011; Lezak et al., 2014; Ramikie and Ressler, 2016; Mercer et al., 2016).
As previously mentioned, PACAP and its receptors display dense distribution within
stress and anxiety related brain areas, including the medial prefrontal cortex, hippocampus,
amygdala, and bed nucleus of the stria terminalis (BNST) (Hashimoto et al., 2011). As to our
knowledge, only one study has examined sex differences in PACAP expression and receptor
distribution without inducing stress, finding that male rats express higher levels of PACAP
within the adrenal gland than females (Mosca et al., 2015). Male rats also displayed significantly
lower levels of PACAP within the superior cervical ganglia, as well as a significantly lower
number of VPAC2 receptors within the hypothalamus as compared to female rats (Mosca et al.,
2015). The scope of this study was limited, focusing only on a few structures, so it is hard to
draw complete conclusions about PACAP-related expression in males and females.
The relationship between PACAP and the BNST has been a strong point of interest
within the Hammack Laboratory. A number of previous studies within the laboratory suggest
that PACAP in the BNST is critical for stress-induced anxiety (Hammack et al., 2009; Hammack
et al., 2010; Lezak et al., 2014; Roman et al., 2014; Hammack and May, 2015; Goode and
Maren, 2017; King et al., 2017). Consequently, the lab is interested in studying PACAP
functioning within the BNST in the context of anxiety-related disorders like PTSD.
The BNST.
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The BNST is a sexually dimorphic structure. General morphology of the BNST differs
between males and females. In male animals, the volume of the medial posterior region of the
BNST is larger than that in females (del Abril et al., 1987; Shah et al., 2004). Conversely, the
medial anterior region of the BNST shows a greater volume in females than in males (del Abril
et al., 1987). Outside of structural differences, it seems that functional connectivity and circuitry
within the BNST also display sex differences. It has been demonstrated that the BNST binds
high levels of sex hormones early in life, which is the period when functional differentiation
occurs (Hines et al., 1985). Because of this, it is likely that this hormone-binding contributes to
both morphological and functional sex differences. Males appear to display more robust
projections to other brain regions, as well as displaying a higher density of arginine vasopressin
and androgen receptors (Hutton et al., 1998; Gu et al., 2003; Han and de Vries, 2003; Shah et al.,
2004). Importantly, females display a higher density of CRH neurons than males, which is
relevant when examining fear and anxiety related behaviors (Uchida et al., 2019).
The BNST is considered to be a part of the extended amygdala, and has been implicated
in the stress response and human psychiatric disorders (Lebow and Chen, 2016). The BNST is
thought to play a role in the mediation of the hypothalamic-pituitary-adrenal axis (HPA), the
sympathetic nervous system, and other central nervous system (CNS) circuits that are engaged
following exposure to a stressor (Walker et al., 2003; Herman et al., 2005; Walker and Davis,
2008; Walker et al., 2009; Radley and Sawchenko, 2011). Importantly, the BNST plays a major
role in the regulation of the paraventricular nucleus (PVN) of the hypothalamus, which then
serves to regulate the HPA axis and endocrine responses to stress (Radley and Sawchenko,
2011). Because of this, it is important to further explore dysregulation of the BNST and how it
contributes to the regulation of other stress-related neurocircuitry.
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The BNST has also been shown to play a critical role in regulating response to longduration stressors. Accordingly, the BNST is argued to function to mediate anxiety-related
behaviors (Walker et al., 2003; Waddell, et al., 2006; Walker and Davis, 2008; Walker, et al.,
2009; Radley and Sawchenko, 2011; Hammack et al., 2015). Based upon these findings, it then
follows that altered or maladaptive BNST functioning is likely involved in the development of
anxiety disorders. It is thought that lengthy exposure to stressors may increase BNST
functioning, leading to anxiety. To evidence this, chronic exposure to stressors has been
associated with enhanced BNST neuroplasticity (Stout et al., 2000; Vyas et al., 2003; Choi et al.,
2006; Pego et al., 2008; Hammack et al., 2009).
Past examinations of the neural basis of PTSD symptomatology have highlighted the role
of the amygdala in the experiencing of flashbacks (Liberzon & Sripada, 2007; Hayes et al., 2011;
Bourne et al., 2013; Storm et al., 2013; Andrewes & Jenkins, 2019). However, anxietyassociated symptoms like hypervigilance also are distinctive markers of PTSD. Because the
BNST has been shown to be heavily involved in anxiety processes, the BNST may contribute to
hypervigilance and enhanced startle observed in PTSD.
To support this, it has previously been demonstrated that veterans diagnosed with PTSD
display amplified dark-enhanced startle behaviors (Grillon et al., 1998). Dark-enhanced startle is
a form of anxiety responding that has been shown to be dependent upon the BNST (Walker et
al., 2009). Kamkwalala et al., 2012 performed a similar study in civilian populations, but found
that dark-enhanced startle was only increased in females diagnosed with PTSD. The
ADCYAP1R1 SNP has also been studied relation to dark-enhanced startle, and has been found to
be associated with increased startle responding in both male and female children (Jovanovic et
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al., 2013). However, when studied in adult populations, dark-enhanced startle is only shown to
be significantly increased in females with the ADCYAP1R1 SNP (Ressler et al., 2011).
Sex Differences in BNST-PACAP Interactions.
Previous work has also demonstrated that sex hormones may differentially affect
PACAP’s functioning within the BNST. It has been found that increased PACAP and PAC 1
transcript levels were found in ovariectomized female rats that were given estradiol (Ressler et
al., 2011). It has also been noted that when PACAP is injected into the posterior BNST, anorexia
and weight loss can be observed in both male and female rats (Kocho-Schellenberg, et al., 2014).
Anorexic behaviors were also found to be stronger in rats that were treated with estradiol, further
suggesting an interaction of estradiol with PACAPergic systems.
Additionally, it has been found that startle amplitude and corticosterone levels increased
following intra-BNST injection of PACAP in male rats that has previously been exposed to CVS
(King et al., 2017). However, CVS was not found to increase startle response in female rats.
However, BNST PAC1 receptor transcripts were shown to be upregulated in both males and
females. These results drew researchers to the conclusion that exposure to stressors alters neural
circuitry in males and females in different ways and intra-BNST PACAP effects are related to
sex, which remains to be clarified.
Based upon this previous literature, it is likely that sex hormones differentially interact
with central PACAP function, thus creating dissimilarities in stress-related neural circuitry.
Interactions between estradiol and PACAP within the BNST are of particular interest, due to the
ADCYAP1R1 SNP being located within an ERE. This suggests that the PAC 1 receptor may be
regulated by estradiol, and could imply that estradiol may regulate PACAP-dependent behaviors
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such as anxiety. Figure 1 illustrates the hypothesized model of estradiol’s interaction with the
ADCYAP1R1 SNP, and how dysregulation within this system may lead to increased incidence of
PTSD symptomatology.
Estradiol, like other sex hormones, fluctuates throughout the estrous cycle in females. In
rats the estrous cycle lasts for four days and consists of four distinct stages—proestrus, estrus,
diestrus 1, and diestrus 2. Estradiol levels rapidly climb and peak during proestrus (Marcondes et
al., 2002). Ovulation occurs at the start of estrus, after which estradiol levels plummet and return
to baseline by the end of estrus (Marcondes et al., 2002; Paccola et al., 2013). Other sex
hormones such as prolactin, luteinizing hormone (LH), and follicle stimulating hormone (FSH)
increase during proestrus and begin to return to baseline levels after estrus (Marcondes et al.,
2002). Progesterone levels have two peaks—one during diestrus 1 and one towards the end of
proestrus, with fluctuating levels in between (Marcondes et al., 2002). See Figure 2 for an
illustration of relative hormone levels over the course of the estrous cycle.
Based upon this background of research, we theorized that increased presence of estradiol
during certain phases of the estrus cycle might interact with PACAPergic circuitry in the BNST,
regulating the behavioral output following BNST PACAP infusion in the form of amplified
anxiety-like responding. We examined this theory in our experiment by looking at the effects of
intra-BNST PACAP on anxiety-like behaviors across the course of the estrous cycle in rats.
Contrary to our initial hypothesis, significantly higher instances of anxiety-like behaviors were
observed in female rats in proestrus and estrus that had been injected with PACAP. Therefore,
we concluded that intra-BSNT PACAP increases anxiety when ovarian hormones are in flux.
Methods
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Subjects.
Adult female Sprague-Dawley rats (225 – 275 g) were purchased from Charles River
Laboratories (Wilmington, MA). After being delivered to the Dewey Hall research facilities, rats
were allowed to habituate for at least five days prior to any experimental procedures. Subjects
were placed in grouped housing prior to surgery, and then were moved to single housing after
cannulation surgeries to ensure optimal recovery conditions. In both housing environments, rats
were maintained on a 12-hour light/dark cycle, with lights turning on at 7:00. Rats had access to
food and water ad libitum both before and after surgery.
The experimental groups consisted of rats in each of the four stages of the estrous cycle
(proestrus, estrus, diestrus 1, and diestrus 2), with the rats in each group having either PACAP or
a vehicle infused. There were eight rats in each experimental group, for a total of sixty-four
subjects. All of the procedures and use of animal subjects were approved by the University of
Vermont’s Animal Care and Use Committee.
Surgical Procedures.
Rats were deeply anesthetized with isoflurane vapor prior to undergoing surgery. The
rats’ heads were completely shaved of fur. Rats were then placed on the surgical table, with their
noses inserted into a nose cone in order to provide and constant and steady supply of isoflurane
and oxygen. Throughout the surgical process, sedation was monitored by using a gentle toe pinch
and checking for physiological response. Thermoregulation was provided with a heating pad.
Rats where then mounted onto the stereotaxic axis by inserting ear bars into the ear canal, and
then tightening into place and ensuring that the head would not move and would maintain its
placement. Lubricant was placed on the rat’s eyes in order to protect them from drying during
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the surgical process. The shaved skin was then cleaned thoroughly with alcohol and iodine. An
incision (about 2 cm long) was then made, and bulldog clamps were used to pull the skin back
and expose the skull. Soft tissue was lightly scrubbed from the skull. Using a scalpel, a scoring
pattern was made upon the skull. The area was then cleaned with hydrogen peroxide to ensure
that the skull was completely dry. Bregma was then marked, and then four holes were drilled into
the surrounding plates, with care being taken so the drill bit did not penetrate into the brain itself.
Four screws were then inserted into each of these holes to provide stability for the headcap.
Additional holes were then drilled at the following coordinates relative to bregma in order to
target the BNST region: 0.4 on the anterior/posterior plane, +3.8 on the medial/lateral plane, and
-5.3 on the dorsal/ventral plane. Using a stereotaxic device, cannulas (26 gauge, Plastics One,
Roanoke, VA) were inserted at a 20-degree angle. Dental cement and dental acrylic liquid were
applied to the skull in order to make a headcap to hold the cannula in place. Following complete
drying of the headcap, Lactated Ringers and carprofen (0.5 mg/kg) were injected
subcutaneously.
Recovery and Estrous Cycle Tracking.
The rats were given at least one week of recovery time following surgery. During this
time, rats were weighed daily and monitored for eating behaviors due to concerns about possible
anorexic behaviors or slow recovery from surgery. Rats were given one additional injection of
carprofen (0.5 mg/kg) on the day following surgery and then on an as-needed basis if the animal
appeared to be in pain.
After this post-op period, vaginal swabs of each rat were taken, and examined for their
cytology in order to determine which phase of the estrous cycle the subject was in (Figure 3).
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Swabs were taken as close to noon as possible. Swabbing continued until an established pattern
was formed and the subsequent phase was able to be accurately predicted. The minimum time
required to accurately determine estrous cycle was four to five days—equating to the observation
of one full estrous cycle.
PACAP Infusion and Elevated Plus Maze Testing.
Behavioral testing for all animals took place in the afternoon (12:00 h – 16:00 h). Rats
were removed from their home cages and gently restrained in a towel. They were then infused
bilaterally via the surgically placed cannulas over a one-minute period with either PACAP
(American Peptide Co., Sunnyvale, CA; 0.1–1 μg in 0.5 μl per side) or a vehicle (0.05% BSA in
saline) using an 11 mm internal cannulae attached to a 10 µL 700 series Hamilton syringe. Rats
were then returned to their home cages and left to sit for fifteen minutes to allow PACAP to take
effect.
Behavioral testing then took place, using an elevated plus maze. The arms of the maze
that measured 60 cm long and 10 cm wide and extended from a 9 cm x 9 cm central platform.
The two enclosed arms had opaque walls that were around 30 cm high. The room in which
behavioral testing took place was dimly lit by bulb emitting red light. Rats were placed in the
maze in the center square facing a closed arm away from the door. Their behavior was then
recorded via an external camera. A five-minute segment of the video was then analyzed by two
observers, both blind to the treatment condition. Analysis of videos began at the time when the
researcher had left the room and the door was completely shut. Those analyzing the videos
recorded time spent in open arms, time spent in closed arms, number of arm entries (defined by
all four paws crossing a border into an open or closed arm), and number of open arm entries.
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Cannula Verification.
Within the days following the completion of behavioral testing procedures, rats were
transcardially perfused with saline followed by 4% paraformaldehyde. Brains were then removed
and fixed with 4% paraformaldehyde for an additional 48 hr before transferring to a 30% sucrose
solution for cryoprotection.
For sectioning within a cryostat, brains were placed within a mold and frozen in TissueTek. 60 micrometer slices were taken and cannula placement was verified visually. If cannula
placement fell outside of the BNST region, subjects were not included in analysis.
Statistics.
Results were first analyzed using Levene’s test for equality of variance. Data was then
examined via factorial ANOVA and pairwise comparisons using SPSS version 27 (IBM
Software, Armonk, NY). Additionally, post hoc Tukey’s comparisons were performed utilizing
the SPSS software.
Results
Cannula Verification.
A visual examination showed that most cannulae were correctly aimed at the region of
the BNST. A total of 5 animals were removed from analysis due to improper cannula placement.
Three of these were treated with PACAP—one within estrus, one within diestrus 1, and one in
diestrus 2. Additionally, two animals in the vehicle condition were removed from the diestrus 2
group.

Estrous Cycle & BNST-PACAP

Deckers 17

Time in Open Arms.
There was an overall effect of PACAP on open arm time, indicative of an anxiogenic
effect, F(1,58) 0.001, p < 0.05. Moreover, there was a significant interaction between estrous
phase and PACAP treatment, F(3,58) 0.042, p < 0.05, suggesting that the increase in the
anxiogenic effects of PACAP depended on phase of estrous. A visual inspection of the data
suggests that the anxiogenic effects of PACAP may be stronger during phases when hormones
are fluctuating significantly (proestrus and estrus), although post-hoc were not able to confirm
these observations. Interestingly, there was no main effect of estrous phase on open arm time,
F(3,58) 0.407, p > 0.05 (Figure 4).
Arm Entries.
In order to determine whether PACAP infusion altered locomotor activity more
generally, the total number of arm entries into open and closed arms were analyzed. The animals
were scored on the number of times that all four paws crossed a border entering an open or
closed arm.
There was no effect of PACAP on total arm entries, F(1,58) 0.134, p > 0.05, indicating
that PACAP does not have an effect on overall locomotion. Additionally, there was no effect of
phase on total arm entries F(3, 58) 0.199, p > 0.05, nor was there a significant interaction
between estrous phase and PACAP treatment F(3,58) 0.289, p > 0.05. Interestingly, while the
interaction was not significant, visual inspection of the data shows that PACAP trended towards
a decrease in total arm entries during proestrus and estrus, consistent with open arm time (Figure
5).
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Open Arm Entries.
In order to determine whether PACAP infusion altered entrances in to open arms alone,
the animals were then scored on the number of times that all four paws crossed a border entering
an open arm.
There was an overall effect of PACAP on open arm entries, indicative of an anxiogenic
effect, F(1,58) 0.010, p < 0.05. However, there was not an effect of phase F(3,58) 0.264 > 0.05
or a significant interaction between estrous phase and PACAP treatment, F(3,58) 0.063, p < 0.05,
suggesting that the increase in the anxiogenic effects of PACAP do not depend on phase of
estrous. A visual inspection of the data suggests that the anxiogenic effects of PACAP may be
stronger during phases when hormones are fluctuating significantly (proestrus and estrus)
(Figure 6).
Open Arm Entries Ratio.
Open arm entries were then examined as a function of total arm entries in order to control
for overall entries (i.e. locomotion).
There was an overall effect of PACAP on the ratio of open arm entries, indicative of an
anxiogenic effect, F(1,58) 0.002, p < 0.05. Despite this, there was not an effect of phase F(3,58)
0.326, p > 0.05 or a significant interaction between estrous phase and treatment F(3,58) 0.187, p
> 0.05. Similar to the above observations, there is a trend towards an increased anxiogenic effect
when treated with PACAP, especially during proestrus and estrus (Figure 7).
Discussion
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Our data suggested that PACAP increased anxiety-like behaviors during both proestrus
and estrus, but PACAP did not increase anxiety-like behavior during the other estrous phases.
Proestrus and estrus are phases in which ovarian hormones, particularly estradiol and
progesterone, are fluctuating rapidly and dramatically. Because there are multiple hormones
changing during this time period, we cannot localize the effects to one hormone alone. Instead,
we can conclude that intra-BNST PACAP infusion results in increased anxiety likely during
estrous cycle phases in which ovarian hormones are in flux.
Previous studies have demonstrated that hormonal flux appears to increase the likelihood
of experiencing mood disturbances and the development of affective disorders (Ahokas et al.,
2001, Parker & Brotchie, 2004, Douma et al., 2005, Solomon and Herman, 2009, McHenry, et
al., 2013). Within our experiment, we also observed that anxiety was not increased during
estrous phases with more stable hormone levels. This provides a potential role for hormone
stability as having a protective effect on anxiety-like behaviors.
While this study did not evaluate the effects of particular hormones, prior work has
highly implicated estradiol’s interactions with the PACAP system, due to the ADCYAP1R1
SNP’s location within an ERE. In order to analyze the effects of estradiol alone, future studies
could be conducted with ovariectomized rats given exogenous estradiol once every four days in
order to simulate fluctuating levels of estradiol without the influence of other female sex
hormones. It would also be recommended that blood serum levels of estradiol should be
collected at the time of behavioral testing and examined in order to confirm hormone levels in a
more precise manner. Doing this will allow for the development of a more precise model of
estradiol-PACAP interactions, and provide more direction for future lines of inquiry.
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Estradiol has two receptors-- ERα and ERβ (Gross & Yee, 2002). These receptors are
differentially distributed within males and females. ERα is primarily expressed within female sex
organs, whereas ERβ is expressed in a much wider variety of cells, but to a higher degree in
females than in males (Chen et al., 2019). ERα and ERβ are two distinct receptors, with nonredundant roles. Both receptors have been found to be associated with different aspects of
synaptogenesis and synaptic plasticity (Bondesson et al., 2014). Additionally, ERα is associated
with behaviors related to mood regulation and is thought to have an anxiogenic effect, whereas
ERβ is implicated in cognitive processes and is associated with anxiolytic properties (Lee et al.,
2012; Borrow & Handa, 2017).
Although the roles of these two receptors are discrete, they both have similar mechanisms
of action. The first of these is the “classical” mechanism of action, which acts to ultimately affect
genomic transcription (Deroo & Korach, 2006). In this mechanism, estrogens diffuse into the cell
and bind to the estrogen receptor (ER) in the nucleus. This estrogen-ER complex will then bind
to EREs. This can occur either directly or indirectly via interactions with proteins within the
promotor region of genes that respond to estrogen. This binding will then function to recruit
coregulatory proteins to the promotor regions, thus facilitating the recruitment of RNA
polymerase II transcriptional activity (Heldring et al., 2007). The exact mechanisms surrounding
this binding are not well understood in terms of ligand specificity, ER subtype specificity, and
interaction domains. Ultimately, this process results in the increase or decrease of mRNA and
changes in associated protein production, which can contribute to alterations in physiological
response. To contextualize this process within PACAPergic systems, Given the ADCYAP1R1
SNP’s location within an ERE, it follows that the presence of estrogen is able to induce changes
in PAC1 expression, potentially contributing to alterations in anxiety-like behavior. This
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regulation will be discussed further below. Importantly, the ER’s classical mechanism of action
is a longer-term mechanism, occurring over the course of multiple hours (Deroo & Korach,
2006).
Conversely, the non-genomic mechanisms of ERs are much faster-acting, and can initiate
an effect on the order of minutes or even seconds. In this case, estrogens interact with ERs or
non-ER estrogen binding proteins located on the plasma membrane (Deroo & Korach, 2006;
Heldring et al., 2007). In this case, binding causes the activation of second messenger cascades
that ultimately function to increase intracellular levels of Ca 2+ or NO, as well as the activation of
kinases. Figure 8 provides an illustration of both the classical and non-genomic pathways
associated with estrogen-binding to ERs.
This division of genomic and non-genomic mechanisms might contribute to the effects
seen within this experiment. The immediate effects of estradiol binding and activating the nongenomic pathway could contribute to significantly increased anxiety seen during proestrus.
However, the classical pathway takes hours to reach its full effect, which means that the elevated
level of estradiol leading up until ovulation in estrus could generate prolonged effects that
generate physiological and behavioral changes even after estradiol levels have begun to decline
and return to baseline (Figure 9). This model could be tested by utilizing a transcription factor
decoy against the promotor region of the ERE (as in Wang et al., 2003 and Lambertini et al.,
2005), thus preventing the estradiol-ER complex binding to this region and effecting downstream
classical effects. By doing this, the non-genomic mechanisms can be isolated and examined with
a greater degree of specificity.
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Because ERα and ERβ have distinct pathways and roles, it is possible that these two
pathways could be selectively stimulated/inhibited and analyzed in relation to a functional role in
anxiety-like pathologies. Potentially, these pathways could be therapeutic targets if they are
found to play specific roles in anxiety-related circuitry. Importantly, half of the neurons in the
principal nucleus of the BNST express ERα, and most of these neurons co-express ERβ
(Shughrue et al., 1998; Leite et al., 2014). The presence of ERα is modulated by the relative
presence of female sex hormones, with higher hormone levels at proestrus correlated with a
lower number of ERα positive neurons within the BNST (Leite et al., 2014). This
downregulation most likely is directly tied to the increased presence of estradiol within the
system, as progesterone has been demonstrated to have no effect on the total number of ERα
positive neurons within the principal nucleus of the BNST (BNSTpr) (Leite et al., 2014).
Additional evidence suggests that ERα and ERβ can be selectively activated, and that activation
of ERβ can result in the modulation of ERα gene transcription (Frasor et al., 2003, Hall and
McDonnell, 1999, Lindberg et al., 2003, Sá et al., 2009, Sá et al., 2013). Thus, it is thought that
estradiol decreases total number of ERα-positive BNSTpr neurons by activating ERβ, which
contributes to a decrease in behavioral and physiological responses associated with ERα alone.
Previous work has demonstrated that the combination of fear conditioning and estradiol
treatment able to induce the expression of PAC 1 receptors through ERα binding and signaling via
the classical mechanism of action (Mercer et al., 2016). In individuals with the ADCYAP1R1
SNP, normal signaling within this pathway is most likely disrupted, causing increased
vulnerability to anxiety-related disorders such as PTSD. Additional work demonstrates that DNA
methylation is reduced by ERα binding, which suggests that epigenetic mechanisms may be
involved in the upregulation of ADCYAP1R1 (Ung et al., 2014).
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In addition to estradiol, progesterone levels show large fluctuations during proestrus and
estrus. Future studies could explore the effects of progesterone alone by utilizing ovariectomized
rats given exogenous progesterone or its metabolite allopregnanolone once every four days to
simulate fluctuating levels of progesterone without the influence of other female sex hormones.
Studies examining the anxiety-related effects of progesterone have produced somewhat
conflicting results. Progesterone is traditionally thought to have anxiolytic properties, mediating
the activity of anxiety-related circuitry through its role as a positive allosteric modulator of
GABAA activity (Picazo & Fernandez-Guasti, 1995; Le Melledo & Baker, 2004; Reddy et al.,
2005; Flores et al., 2020). However, some evidence in humans suggests that progesterone can
have anxiogenic effects by selectively increasing amygdala reactivity (van Wingen et al., 2007;
Reynolds et al., 2018), which may be due to changes in GABA A expression over the course of
the estrous cycle, but this effect remains to be completely elucidated (Maguire et al., 2005).
Interestingly, several studies have reported that rapid decreases in progesterone levels may
increase anxiety-like behavior (Perna et al., 1995; Smith et al., 1998; Gulinello et al., 2002;
Smith et al., 2006; Nillni et al., 2011), which may be relevant for the increased anxiety-like
behavior seen during estrus within our experiment.
Research examining LH and FSH is somewhat limited, but there is some evidence to
demonstrate that both may have anxiogenic effects (Warnock & Bundren, 1997). Additional
studies similar to the proposed estradiol/progesterone examinations would allow for further
untangling of complex interactions between the individual ovarian hormones and stress-related
neurocircuitry.
Although results of this experiment did seem to point to heightened anxiety behaviors in
PACAP-treated animals during phases in which ovarian hormones are in flux, we did not
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perform post-hoc analyses in order to confirm this observation. Because of this, it is possible that
this effect was actually restricted to one estrous cycle phase. If this is the case, it seems likely
that the effect is localized within estrous as opposed to proestrus based upon a visual observation
of the data. This would mean that PACAP increases anxiety-like behaviors in phases with
especially low ovarian hormone levels. Several studies have reported that low ovarian hormone
levels are associated with an increased display of anxiety-related behaviors (Zimmerberg &
Farley, 1993; deChaves et al., 2009; Lebron-Milad & Milad, 2012; American Physiological
Society, 2018), but the interaction between low female sex hormone levels and PACAPergic
circuitry has not been explored. To examine this question, future studies could be conducted with
ovariectomized rats given no hormone replacements in order to simulate especially low hormone
levels.
An additional avenue to explore is potential sex differences in PACAPergic signaling. As
mentioned earlier, there are multiple pathways that can be stimulated by PACAP binding to its
receptors. Generally, PAC1 is thought to be positively coupled to adenylyl cyclase and
phospholipase C. However, it has previously been shown that different variants of the PACAP
receptor result in differential signal transduction (Spongier et al., 1993; Zhou et al., 2002).
Depending on which PAC1 isoform is present, PACAP binding can differentially act through Gs,
Gq, or β-arrestin in order to activate multiple canonical signaling pathways, including
AC/cAMP/PKA, PLC/DAG/IP3/PKC, cAMP/NCS-RapGef2/Rep1/MEK, and MEK/ERK (King
et al., 2017; Johnson et al., 2019). Through these pathways, PAC 1 receptor signaling is able to
mediate a wide variety of cellular functions., and can produce diverse downstream consequences.
This can include enhanced neurotransmitter and neuropeptide synthesis and release, and changes
in structural plasticity within stress and anxiety-related neurocircuitry (King et al., 2017). Both
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forms of VPAC receptors are thought to couple Gs, activating adenylyl cyclase, and increasing
intracellular cAMP levels (Laburthe & Couvineau, 2002; Laburthe et al., 2007; Johnson et al.,
2019). There have been other studies that have provided evidence that VPAC receptors might
also trigger biological responses through other signaling pathways, although findings from these
studies have been slightly contradictory (Laburthe & Convineau, 2002). Further clarity is needed
in order to illuminate the exact functioning and downstream effects of these receptors.
Sex differences in coupling and functioning should be examined within these signaling
cascades. Sex differences have been found within other stress and anxiety-related receptor
activity, particularly within CRH systems. The CRH1 receptor is normally coupled to either βarrestin and Gs pathways. However, following exposure to stress, CRH1 receptors in females
demonstrates decreased linkage to β-arrestin, and enhanced coupling to Gs (Bangasser et al.,
2010). This results in an amplified response to acute stress in females, as well as a weakened
ability to develop compensatory mechanisms in response to chronic stress. These findings are
especially important in light of the similarities between the PAC 1 receptors and CRH1—both
belong to the Class B family of seven transmembrane G-protein coupled receptors, and activate
similar downstream signaling pathways following ligand binding (Valentino et al., 2013). Thus,
it is possible that analogous sex differences may occur within PACAPergic systems, with estrous
cycle phase biasing the type of PACAP signaling pathway utilized.
Another route of exploration could be to examine if physiological changes in
PACAPergic systems correlate hormonal fluctuations across the course of the estrous cycle.
Transcript levels for all of the PACAP receptors (PAC1, VPAC1, and VPAC2) should be
examined during each of the four phases of the estrous cycle in order to see if the expression
pattern of receptors is changing throughout the estrous cycle. It is necessary to analyze mRNA
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transcript levels for all three of PACAP’s receptors in order to fully account for any changes or
fluctuations that might be taking place. In conjunction with this, western blots should be
conducted to analyze any changes in actual protein levels associated with mRNA transcripts, as
changes in transcript level do not necessarily equate to changes in protein production/presence.
These physiological changes within the context of PACPergic-BNST symptoms are
valuable to explore, as they may contribute to increased incidence of BNST-mediated anxietyrelated symptomatology (as discussed within the introduction). As females with PTSD report
higher incidence of hypervigilance and hyperarousal (i.e., anxiety-related symptoms) than men,
changes in PTSD-related PACAPergic circuitry may contribute to increased susceptibility to
anxiety phenotypes during certain phases of the estrous cycle (Birkeland et al., 2017).
Studies have demonstrated that rats within the proestrus and estrus stages have enhanced
contextual fear acquisition and extinction (Chang et al., 2009). This finding was replicated in
human females, using analogous menstrual cycle phases, noting that low estradiol levels were
associated with continued expression of fear responses during the extinction phase (LebronMilad & Milad, 2012). Furthermore, women with low estradiol levels during extinction reported
a higher incidence of intrusive thoughts within the following days, which may suggest both a
phasic vulnerability and protective effect based upon whether fear extinction or acquisition is
taking place. Importantly, this may provide a potential pathway for optimized therapeutic
treatments for PTSD patients—perhaps administration of exogenous estrogen could help to
increase the efficacy of cognitive behavioral therapy.
The findings of this experiment contribute to current knowledge surrounding sexdependent differences in male and female stress responses. These results suggest that perhaps
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hormone fluctuations might sensitize anxiety-related neurocircuitry, causing increased incidence
of stress responding and anxiety-like behaviors. Continuing to examine PACAPergic BNST
neurocircuitry in relation to female sex hormones is warranted, as understanding of this system
could lead to a clearer portrait of maladaptive functioning of anxiety-related neurocircuitry.
Through this area of study, viable therapeutic targets and techniques could be developed and
implemented in order to try and mitigate the presence and effects of anxiety-related disorders
such as PTSD in women.
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Figures and Tables
Table 1. Genetic markers that have been associated with PTSD.
Gene Name

Functional Role

Other Relevant Information

Sources

MAD1L1

Component of mitotic spindle assembly
checkpoint; prevents onset of anaphase until
chromosomes are aligned properly along
metaphase plate

Associated with PTSD across racial and ethnic
groups; also associated with schizophrenia
and bipolar disorder

Stein et al., 2021

Encodes CRHR1, a corticotropin releasing
hormone receptor

Associated with intrusive symptoms of PTSD;
antagonism of CRHR1 has not been found to
be an effective PTSD treatment

CRHR1

Ripke et al., 2014
Stahl et al., 2019
Stein et al., 2021
Gelernter et al.,
2019
Dunlop et al., 2017

TSNARE1

Involved in intracellular protein transport,
particularly in SNARE binding and SNAP
receptor activity

Associated with risk taking behaviors,
schizophrenia

Stein et al., 2021
Plooster et al.,
2021
Linner et al., 2019

EXD3

PARK2

PACRG

ADCYAP1R1

Involved in nucleic acid binding and 3’ to 5’
exonuclease activity

Negatively correlates with PTSD diagnosis,
with relationship mediated by socioeconomic
status

Stein et al., 2021

Precise function not known

Connected with susceptibility to leprosy,
Parkinson’s Disease

Stein et al., 2021

Encodes Parkin Coregulated, a gene that can
function to suppress cell death and may be
involved in the formation of Lewy bodies

Connected with susceptibility to leprosy,
Parkinson’s Disease

Stein et al., 2021

Encodes PAC1, a pituitary adenylate cyclase
activating polypeptide receptor

Single nucleotide polymorphism within an
estrogen response element is associated
with PTSD in females

Ressler et al., 2011

Polimanti et al.,
2019

Meschede et al.,
2020

Meschede et al.,
2021

Mercer et al., 2016
Smoller, 2016

* this is not an exhaustive list of all genes that have been associated with PTSD
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Figure 1. A proposed model for estradiol-PAC1 interactions in both normal conditions, and in
the presence of the ADCYAP1R1 SNP. From “Stress-related disorders, pituitary adenylate
cyclase-activating peptide (PACAP)ergic system, and sex differences”. Ramikie, T.S. & Ressler,
K.J. (2016). Dialogues in Clinical Neuroscience, Vol 18(4): 403 – 413. DOI:
10.31887/DCNS.2016.18.4/kressler.

Left: In normal responding, experience of a traumatic event activates stress systems, including
PACAPergic circuitry. Any estradiol within the system is able to bind normally to the ERE. This
causes normal fear and stress responding. Right: Experience of a traumatic event activates stress
systems, including PACAPergic circuitry. However, because the variant ERE is present
(indicated by the red dot), these PACAPergic systems do not activate normally, causing
dysregulation within the stress response. This leads to increased display of fear and stress (i.e.
PTSD-like symptoms).
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Figure 2. Levels of female sex hormones over the course of the rat estrous cycle. From “Estrous
Stage Determination in Rats by Means of Scanning Electron Microscopic Images of Uterine
Surface Epithelium”. Spornitz, U.M.; Socin, C.D.; Dravid, A.A. (1999). The Anatomical Record,
Vol. 254: 116 – 126. DOI: 10.1002/(SICI)1097-0185(19990101)254:1<116::AIDAR15>3.0.CO;2-X

Top Left: Estradiol (E2) levels over the course of the rat estrous cycle. Top Right: Follicle
Stimulating Hormone (FSH) levels over the course of the rat estrous cycle. Bottom Left:
Progesterone (Prog.) levels over the course of the rat estrous cycle. Bottom Right: Luteinizing
Hormone (LH) levels over the course of the rat estrous cycle.
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Figure 3. Vaginal cytology across estrous cycle phases. From “Study on the Estrous Cycle
Regularity of Cryopreserved Rat Ovarian Tissues after Heterotopic Transplantation”. Jafarey, R.
& Jaffri, S.A.R.S. (2016). Open Journal of Obstetrics and Gynecology, Vol. 6: 293 – 298. DOI:
10.4236/ojog.2016.65037

A: Proestrus vaginal smear, marked by the predominance of nucleated epithelial cells (E). B:
Estrus vaginal smear, marked by the predominance of anucleated cornified cells (C). C: Diestrus
1 vaginal smear, marked by equal proportions of leukocytes (L), anucleated cornified cells (C),
and nucleated epithelial cells (E). D: Diestrus 2 vaginal smear, marked by the predominance of
leukocytes (L).
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Figure 4. Time Spent in Open Arms vs. Phase/Treatment.

Phase/treatment interaction and main effects were analyzed via factorial ANOVA. Interaction
between phase and treatment is significant, p = 0.042 < 0.05. Main effect for treatment is
significant, p = 0.001 < 0.05. Main effect for phase is not significant, p = 0.407 > 0.05.
Anxiogenic effects of PACAP appear to be increased during phases in which hormones are
fluctuating significantly (i.e., proestrus and estrus).
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Figure 5. Number of Arm Entries vs. Phase/Treatment.

Phase/treatment interaction and main effects were analyzed via factorial ANOVA. Interaction
between phase and treatment is not significant, p = 0.289 > 0.05. Main effect for treatment is not
significant, p = 0.134 > 0.05. Main effect for phase is not significant, p = 0.199 > 0.05.
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Figure 6. Number of Open Arm Entries vs. Phase/Treatment.

Phase/treatment interaction and main effects were analyzed via factorial ANOVA. Interaction
between phase and treatment is not significant, p = 0.063 > 0.05. Main effect for treatment is
significant, p = 0.010 < 0.05. Main effect for phase is not significant, p = 0.264 > 0.05.
Anxiogenic effects of PACAP appear to be increased during phases in which hormones are
fluctuating significantly (i.e., proestrus and estrus).
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Figure 7. Ratio of Open Arm Entries to Total Arm Entries vs. Phase/Treatment

Phase/treatment interaction and main effects were analyzed via factorial ANOVA. Interaction
between phase and treatment is not significant, p = 0.187 > 0.05. Main effect for treatment is
significant, p = 0.002 < 0.05. Main effect for phase is not significant, p = 0.187 > 0.05.
Anxiogenic effects of PACAP appear to be increased during phases in which hormones are
fluctuating significantly (i.e., proestrus and estrus).
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Figure 8. Mechanisms of estrogen action. From “Estrogen receptors and human disease”. Deroo,
B.J. & Korach, K.S. (2006). The Journal of Clinical Investigation, Vol. 116(3): 561 – 570. DOI:
10.1172/JCI27987

The “classical” pathway, in which estrogen diffuses through the plasma membrane and binds to
ERs within the cell nucleus. ii. Non-genomic pathway, in which estrogen binds to ERs on the
plasma membrane and then leads to downstream effects through second messenger signaling. iii.
Estrogen may also act in a non-genomic manner by binding to non-ER membrane associated
estrogen binding proteins. After binding, effects will continue in a similar manner as (ii).

Estrous Cycle & BNST-PACAP

Deckers 47

Figure 9. Proposed Model for PACAP-Mediated Increased Anxiety-Like Behavior.

The division of genomic and non-genomic mechanisms may contribute to increased anxiety-like
behavior during proestrus and estrus in rats that have been treated with intra-BNST PACAP. The
immediate effects of estradiol binding to transmembrane estrogen receptors results in modulation
of the activity of the PAC1 receptor, ultimately leading to amplified anxiety-like behavior during
proestrus. In the classical pathway, estradiol diffuses into the cell and binds to estrogen receptors
(ER) within the nucleus. The estradiol-ER complex then alters genomic transcription, taking
hours to fully take effect. Thus, the elevated level of estradiol leading up until ovulation in estrus
could generate prolonged effects that cause physiological and behavioral changes even after
estradiol levels have begun to decline and return to baseline.

